| Literature DB >> 36033194 |
Lydia Brock1, Brooke Hightower1, Ty Moore1, Danya Nees1, Benjamin Heigle1, Samuel Shepard1, Micah Kee1, Ryan Ottwell1,2, Micah Hartwell1,3, Matt Vassar1,3.
Abstract
Purpose: To evaluate the completeness of patient-reported outcomes (PROs) reporting using Consolidated Standards of Reporting Trials Patient-Reported Outcome (CONSORT-PRO) in randomized controlled trials (RCTs) involving rotator cuff injuries.Entities:
Year: 2022 PMID: 36033194 PMCID: PMC9402470 DOI: 10.1016/j.asmr.2022.04.032
Source DB: PubMed Journal: Arthrosc Sports Med Rehabil ISSN: 2666-061X
Fig 1Rationale for exclusion.
Characteristics of Randomized Controlled Trails and Bivariate Associations With CONSORT-PRO Completion
| Characteristic | Total 33 (100) | Coef. (SE) | t | |
|---|---|---|---|---|
| Year of publication, No. (%) | ||||
| <2014 | 9 (27.27) | 1 (Ref) | – | – |
| ≥2014 | 24 (72.73) | –3.97, (6.08) | –0.65 | .519 |
| Intervention of RCT, No. (%) | ||||
| Combination | 4 (12.12) | 1 (Ref) | – | – |
| Device | 1 (3.03) | –10.42, (17.38) | –0.6 | .554 |
| Drug | 6 (18.18) | –18.47, (10.03) | –1.84 | .077 |
| Other | 2 (6.06) | –13.75, (13.46) | –1.02 | .316 |
| Surgical | 1 (3.03) | –33.75, (17.38) | –1.94 | .063 |
| Surgical technique | 8 (24.24) | –15.83, (9.52) | –1.66 | .108 |
| Therapy | 11 (33.33) | –14.03, (9.08) | –1.55 | .134 |
| Includes COI statement, No. (%) | ||||
| No statement | 3 (9.09) | 1 (Ref) | – | – |
| Reports COI | 12 (36.36) | –1.09, (10.14) | –0.11 | .915 |
| Reports No COI | 18 (54.55) | –5.93, (9.8) | –0.6 | .55 |
| Journal requirement of reporting guidelines, No. (%) | ||||
| Not mentioned | 8 (24.24) | 1 (Ref) | – | – |
| Recommended | 10 (30.3) | 0.14, (7.53) | 0.02 | .986 |
| Required | 15 (45.45) | 2.86, (6.95) | 0.41 | .684 |
| Mention of CONSORT or CONSORT-PRO within RCT, No. (%) | ||||
| No | 31 (93.94) | 1 (Ref) | – | – |
| Yes | 2 (6.06) | 9.19, (11.32) | 0.81 | .423 |
| PRO as a primary or secondary outcome, No. (%) | ||||
| Primary | 30 (90.91) | 1 (Ref) | – | – |
| Secondary | 3 (9.09) | 1.63, (9.49) | 0.17 | .864 |
| Overall ROB, No. (%) | ||||
| High | 1 (3.03) | 1 (Ref) | – | – |
| Some concern | 29 (87.88) | –11.14, (16) | –0.7 | .492 |
| Low | 3 (9.09) | –5.56, (18.16) | –0.31 | .762 |
| Length of PRO follow-up | ||||
| 3 months or less | 12 (36.36) | 1 (Ref) | – | – |
| 3+ to 6 months | 2 (6.06) | –21.94, (11.41) | –1.92 | .064 |
| 6+ months to 1 year | 8 (24.24) | 4.31, (6.82) | 0.63 | .533 |
| 1 years + | 11 (33.33) | 1.64, (6.24) | 0.26 | .795 |
| Sample size | ||||
| Mean (SD) | 85.27 (56.98) | 0.1, (0.04) | 2.3 | |
| Reported PROMIS measures | ||||
| Not reported | 33 (100.0) | – | – | |
| Reported | 0 (0.0) | – | – |
COI, conflict of interest; CONSORT, Consolidated Standards of Reporting Trials; CONSORT-PROs; PROMIS, Patient-Reported Outcomes Measurement Information System; RCT, randomized controlled trial; SD, standard deviation.
A P-value less than or equal to 0.05 was considered statistically significant indicated in bold.
Completion of CONSORT-PRO by Primary and Secondary Objective Designation
| Primary 30 (90.91) | Secondary Endpoint 3 (9.09) | Total 33 (100) | ||||
|---|---|---|---|---|---|---|
| Complete | Not Complete | Complete | Not Complete | Complete | Not Complete | |
| CONSORT-PRO item | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Introduction | ||||||
| P1b. Abstract—PRO as primary/secondary endpoint | 28 (93.33) | 2 (6.67) | 2 (66.67) | 1 (33.33) | 30 (90.91) | 3 (9.09) |
| 2a. Rationale for including PRO endpoint | 0 (0) | 30 (100) | 0 (0) | 3 (100) | 0 (0) | 33 (100) |
| P2bi. PRO hypothesis present | 6 (20) | 24 (80) | 0 (0) | 3 (100) | 6 (18.18) | 27 (81.82) |
| P2bii. PRO domains in hypothesis | 1 (3.33) | 29 (96.67) | 0 (0) | 3 (100) | 1 (3.03) | 32 (96.97) |
| Methods | ||||||
| P6ai. Evidence of PRO instrument validity | 26 (86.67) | 4 (13.33) | 2 (66.67) | 1 (33.33) | 28 (84.85) | 5 (15.15) |
| P6aii. Statement of the person completing the questionnaire | 15 (50) | 15 (50) | 2 (66.67) | 1 (33.33) | 17 (51.52) | 16 (48.48) |
| P6aiii. Mode of administration (paper, e-PRO) | 3 (10) | 27 (90) | 0 (0) | 3 (100) | 3 (9.09) | 30 (90.91) |
| P7a. How sample size was determined (not required unless PRO is a primary endpoint) | 25 (83.33) | 5 (16.67) | – | – | 25 (83.33) | 5 (16.67) |
| P12a. Statistical approach for dealing with missing data (imputation, exclusion, other) | 6 (20) | 24 (80) | 2 (66.67) | 1 (33.33) | 8 (24.24) | 25 (75.76) |
| Results | ||||||
| 13ai. Report no. questionnaires submitted/available for analysis at baseline | 28 (93.33) | 2 (6.67) | 3 (100) | 0 (0) | 31 (93.94) | 2 (6.06) |
| 13aii. Report no. questionnaires submitted/available for analysis principal time point for analysis | 27 (90) | 3 (10) | 3 (100) | 0 (0) | 30 (90.91) | 3 (9.09) |
| 15. Demographics table includes baseline PRO | 12 (40) | 18 (60) | 1 (33.33) | 2 (66.67) | 13 (39.39) | 20 (60.61) |
| 16. Number of pts (denominator) included in each PRO analysis | 14 (46.67) | 16 (53.33) | 2 (66.67) | 1 (33.33) | 16 (48.48) | 17 (51.52) |
| 17ai. PRO results reported for the hypothesized domains and time point specified in the hypothesis—OR—reported for each domain of the PRO questionnaire if no PRO hypothesis provided | 6 (20) | 24 (80) | 2 (66.67) | 1 (33.33) | 8 (24.24) | 25 (75.76) |
| 17aii. Results include confidence interval, effect size or some other estimate of precision | 28 (93.33) | 2 (6.67) | 3 (100) | 0 (0) | 31 (93.94) | 2 (6.06) |
| 18. Results of any subgroup/adjusted/exploratory analyses | 10 (33.33) | 20 (66.67) | 1 (33.33) | 2 (66.67) | 11 (33.33) | 22 (66.67) |
| Discussion | ||||||
| P20. PRO study limitations | 27 (90) | 3 (10) | 3 (100) | 0 (0) | 30 (90.91) | 3 (9.09) |
| P21. Implications of PRO results for generalizability, clinical practice | 6 (20) | 24 (80) | 1 (33.33) | 2 (66.67) | 7 (21.21) | 26 (78.79) |
| 22. PROs interpreted in relation to clinical outcomes | 12 (40) | 18 (60) | 1 (33.33) | 2 (66.67) | 13 (39.39) | 20 (60.61) |
CONSORT-PRO, Consolidated Standards of Reporting Trials Patient-Reported Outcomes.
Item P7a only applies to PROs identified as primary outcomes.